GSA Capital Partners’s Ascendis Pharma A/S ASND Stock Holding History

GSA Capital Partners’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,717	Closed	-$236K	–	1637
2024 Q4	$236K	Buy	+1,717	New	+$226K	0.02%	1334
2024 Q2	–	Sell	-6,564	Closed	-$992K	–	1613
2024 Q1	$992K	Buy	+6,564	New	+$937K	0.08%	443
2022 Q1	–	Sell	-8,175	Closed	-$1.1M	–	1393
2021 Q4	$1.1M	Buy	+8,175	New	+$1.22M	0.14%	168
2020 Q4	–	Sell	-2,676	Closed	-$413K	–	1195
2020 Q3	$413K	Buy	+2,676	New	+$385K	0.07%	511
2020 Q1	–	Sell	-2,174	Closed	-$302K	–	1051
2019 Q4	$302K	Buy	+2,174	New	+$242K	0.04%	1018
2016 Q3	–	Sell	-13,100	Closed	-$174K	–	1756
2016 Q2	$174K	Sell	13,100 -5,600	-30%	-$86.3K	0.01%	1609
2016 Q1	$347K	Buy	+18,700	New	+$332K	0.02%	1229

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GSA Capital Partners's ASND Position: Q1 2025 in Review

GSA Capital Partners sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 1,717 shares — an estimated $236K sold.

GSA Capital Partners first reported a position in ASND in Q1 2016 and held it in 7 quarters. The position peaked at $1.1M in Q4 2021. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

GSA Capital Partners reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
GSA Capital Partners sold 1,717 Ascendis Pharma A/S shares in Q1 2025, an estimated $236K.
GSA Capital Partners first reported a position in Ascendis Pharma A/S in Q1 2016 and held it in 7 quarters.
GSA Capital Partners's Ascendis Pharma A/S position peaked at $1.1M in Q4 2021.
244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on GSA Capital Partners's 13F filing for Q1 2025, filed 8 May 2025.